Both projects and programs are opportunities for direct member involvement to help benefit the biopharmaceutical manufacturing community, but they have some key complementary differences.
We achieve our mission through an RFx process that aims to advance technical and workforce development projects:
RFP 7.1 includes both technology development and workforce development topics, with a funding amount of up to $4 million. It is open to current NIIMBL members and to new members by the close of the full proposal deadline (December 7, 2023).
Be sure to download the full RFP document for information on submitting either Technology Development or Workforce Development proposals.
Funding amount: Up to $4 million
Technology Development Topics
Workforce Development Topics
RFI 2023.1 – Next-Generation Sequencing (NGS) Method Development Study – aims to promote collaboration among multiple laboratories and industry partners to enhance the reliability, consistency, and understanding of AAV vector properties using NGS-based analysis methods. (Closed September 5, 2023)
The objectives for this study are method development, sharing of best practices, and the establishment of a common protocol amongst the project teams. Depending upon the study outcome, subsequent stages would be planned in the future.
Student applications are currently being accepted for the 2024 NIIMBL eXperience, a week-long program, designed to introduce Black, Latinx, and Indigenous college students to career possibilities in the biopharmaceutical industry. NIIMBL has awarded $370K to five program locations across the country.
2024 Locations
Eligibility Criteria
Application Deadline: March 1, 2024 (5:01 PM EST)
NIIMBL is pleased to announce the pilot of a faculty sabbatical in industry program. The NIIMBL Faculty Fellows program provides financial support for faculty or instructional staff at universities and community colleges to pursue a sabbatical either at an industry member (Tier 1 or Tier 2) or at NIIMBL’s Headquarters (NIIMBL HQ) in Delaware to support NIIMBL-led projects.
Objectives
Requirements
RFP 7.1
RFP 7.1 includes both technology development and workforce development topics, with a funding amount of up to $4 million. It is open to current NIIMBL members and to new members by the close of the full proposal deadline (December 7, 2023).
Be sure to download the full RFP document for information on submitting either Technology Development or Workforce Development proposals.
Funding amount: Up to $4 million
Technology Development Topics
Workforce Development Topics
RFI 2023.1: Viral Vectors
RFI 2023.1 – Next-Generation Sequencing (NGS) Method Development Study – aims to promote collaboration among multiple laboratories and industry partners to enhance the reliability, consistency, and understanding of AAV vector properties using NGS-based analysis methods. (Closed September 5, 2023)
The objectives for this study are method development, sharing of best practices, and the establishment of a common protocol amongst the project teams. Depending upon the study outcome, subsequent stages would be planned in the future.
RFA: NIIMBL eXperience
Student applications are currently being accepted for the 2024 NIIMBL eXperience, a week-long program, designed to introduce Black, Latinx, and Indigenous college students to career possibilities in the biopharmaceutical industry. NIIMBL has awarded $370K to five program locations across the country.
2024 Locations
Eligibility Criteria
Application Deadline: March 1, 2024 (5:01 PM EST)
RFA: Faculty Fellows
NIIMBL is pleased to announce the pilot of a faculty sabbatical in industry program. The NIIMBL Faculty Fellows program provides financial support for faculty or instructional staff at universities and community colleges to pursue a sabbatical either at an industry member (Tier 1 or Tier 2) or at NIIMBL’s Headquarters (NIIMBL HQ) in Delaware to support NIIMBL-led projects.
Objectives
Requirements
NIIMBL funded 32 coronavirus response projects to multiple organizations across the United States.
NIIMBL awarded approximately $1.7M through the Institute’s Global Health Fund (GHF) for projects focused on the development of in vitro potency assays for vaccines being produced by mRNA and/or viral vector technologies.
As of June 30, 2023
December 2023
LigaTrap Technologies, LLC, Merck & Co., Inc., MilliporeSigma/EMD Serono, North Carolina State University, Rensselaer Polytechnic Institute
August 2023
North Carolina State University
August 2023
PATH Center for Vaccines Innovation & Access
August 2023
Fraunhofer USA
November 2022
Merck & Co., Inc., Pfizer, Inc., University of Maryland Baltimore
Mission
Accelerate the development and adoption of data-driven innovation and standards to increase the speed and resilience of biopharmaceutical manufacturing.
Vision
Data-driven technologies optimize the productivity of biopharmaceutical manufacturing and accelerate the delivery of high-quality medicines to patients.
By 2029, the PI program proposes to invent, design, demonstrate, and support commercialization of integrated biopharmaceutical manufacturing technology to transform drug substance (DS) and drug product (DP) manufacturing capability, enabling the following:
Mission
Accelerate the implementation of new vaccine manufacturing technologies across multiple platform processes by addressing workforce and technology issues that U.S. and global vaccine manufacturers and suppliers face and establishing a Center of Excellence for Vaccine Analytics and Assays.
Vision
Accelerate the production of innovative vaccines by ensuring that both U.S.-based and global vaccine manufacturers and suppliers have adequate support to implement advanced manufacturing and product characterization processes.
Mission
Develop and make broadly available a robust, economically viable, shared-access platform for the technical development, manufacturing, and characterization of AAV-based gene therapy vectors. Ensure that workforce training for this platform can integrate into existing curriculum or training models to encourage adoption, and integrate improvements into the platform based on feedback from these training programs.
Vision
A gene-based therapeutics industry capable of serving patients across the full spectrum of unmet needs—from prevalent indications to ultra-rare diseases—that has access to high-quality viral vectors without cost or speed limitations.
Big data
Mission
Accelerate the development and adoption of data-driven innovation and standards to increase the speed and resilience of biopharmaceutical manufacturing.
Vision
Data-driven technologies optimize the productivity of biopharmaceutical manufacturing and accelerate the delivery of high-quality medicines to patients.
Process intensification
By 2029, the PI program proposes to invent, design, demonstrate, and support commercialization of integrated biopharmaceutical manufacturing technology to transform drug substance (DS) and drug product (DP) manufacturing capability, enabling the following:
Vaccine manufacturing
Mission
Accelerate the implementation of new vaccine manufacturing technologies across multiple platform processes by addressing workforce and technology issues that U.S. and global vaccine manufacturers and suppliers face and establishing a Center of Excellence for Vaccine Analytics and Assays.
Vision
Accelerate the production of innovative vaccines by ensuring that both U.S.-based and global vaccine manufacturers and suppliers have adequate support to implement advanced manufacturing and product characterization processes.
Viral vector manufacturing & analytics
Mission
Develop and make broadly available a robust, economically viable, shared-access platform for the technical development, manufacturing, and characterization of AAV-based gene therapy vectors. Ensure that workforce training for this platform can integrate into existing curriculum or training models to encourage adoption, and integrate improvements into the platform based on feedback from these training programs.
Vision
A gene-based therapeutics industry capable of serving patients across the full spectrum of unmet needs—from prevalent indications to ultra-rare diseases—that has access to high-quality viral vectors without cost or speed limitations.
The NIIMBL eXperience is a hands-on, expenses-paid week-long program for college first years and sophomores to gain real-world insight into career possibilities in biopharmaceutical manufacturing.
It’s also an opportunity for NIIMBL academic or non-profit Member organizations to serve as regional lead organizations that will plan, recruit students, and run a NIIMBL eXperience program in their region.
The NIIMBL Faculty Fellows program provides financial support for faculty or instructional staff at universities and community colleges to pursue a sabbatical either at an industry member or at NIIMBL’s Headquarters in Delaware to support NIIMBL-led projects.
We offer a variety of membership options that give you the flexibility to choose your organization’s level of engagement based on technology interests and priorities.